top of page
Funded by a $24,000,000 grant through the federal
New Frontiers in Research Program, the TRanslational Initiative to DErisk NeuroTherapeutics
(TRIDENT) platform is offers a transformative approach to the preclinical evaluation of neurotherapeutics. TRIDENT will dramatically improve the odds of success of neurotherapeutics in clinical trials for the benefit of humans across the globe.
One Platform.
3 Integrated Model Systems.
Our Partners
LEADING ACADEMIC COLLABORATION
Contact Us
bottom of page